Can invisible electric fields quiet the Brain's seizure signals?
NCT ID NCT06716866
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial tests whether a non-invasive technique called temporally-interfering electric field stimulation (TIEFS) can reduce abnormal brain activity linked to epilepsy. Researchers will measure seizure-related signals in patients with medial temporal lobe epilepsy who are already undergoing brain monitoring. The study compares these signals during no stimulation, sham stimulation, and active TIEFS to see if the device can dampen them.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- temporally-interfering electric field stimulation (TIEFS), a non-invasive device that uses electric fields to modulate brain activity
- What this could lead to
- If effective, this could offer a non-invasive, drug-free way to reduce seizure-related brain activity, potentially leading to a new treatment for epilepsy.
- What could go wrong
- This is an early, exploratory study focused on brain signals, not seizure outcomes. The effect may not translate to real-world seizure reduction, and the device's safety and efficacy are not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2019
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients undergoing invasive intracranial EEG studies Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Epilepsy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites in 2 countries. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
St. Anne Hospital, Masaryk University
Brno, Czechia
-
UC Davis Medical Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lavender and lullabies help kids with epilepsy sleep better?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Can a Comfort-Focused education program improve life with epilepsy?
- Can video games rewire young brains after injury?
- High-Fat Diet's effect on epilepsy: scientists track brain signals
- Epilepsy drug candidate put to the test in healthy volunteers